Kim has extensive experience of developing an understanding of the fate and effects of small molecules in biological systems. As a biologist with a mathematical leaning, Kim’s career in ICI (latterly Syngenta) from 1988 to 2019 started in environmental and human exposure modelling and risk assessment for small molecules, followed by 16 years in mammalian toxicology and metabolism groups. His expertise is in understanding and modelling the mammalian kinetics of small molecules, including study design and interpretation, and the relationship to biological effects (desired or otherwise). He has also worked on new molecule discovery projects. Kim has published and presented extensively, and worked on many panels and committees as a recognised expert (e.g. ECETOC, ECPA, CLI, IVA, BBSRC, NC3Rs, FOCUS).